在急性髓性白血病中克服CD226相关的免疫逃避,使用CD38 CAR工程NK细胞

Luciana Melo Garcia1, Achintyan Gangadharan2, Pinaki Banerjee3

  • 1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Medicine, Université Laval, Quebec City, QC G1V 0A6, Canada; Hematology-Oncology Service, CHU de Québec - Université Laval, Quebec City, QC G1V 0A6, Canada.

Cell reports
|January 4, 2025
PubMed
概括

对急性髓性白血病 (AML) 的自然杀手 (NK) 细胞细胞毒性受到低CD226表达的损害. 工程化CAR38NK细胞可以克服这一问题,提供潜在的AML疗法.